NI201900009A - MÉTODOS PARA TRATAR EL CÁNCER DE PRÓSTATA Se describen métodos para tratar el c - Google Patents

MÉTODOS PARA TRATAR EL CÁNCER DE PRÓSTATA Se describen métodos para tratar el c

Info

Publication number
NI201900009A
NI201900009A NI201900009A NI201900009A NI201900009A NI 201900009 A NI201900009 A NI 201900009A NI 201900009 A NI201900009 A NI 201900009A NI 201900009 A NI201900009 A NI 201900009A NI 201900009 A NI201900009 A NI 201900009A
Authority
NI
Nicaragua
Prior art keywords
methods
prostate cancer
treat prostate
treat
subject
Prior art date
Application number
NI201900009A
Other languages
English (en)
Inventor
Gottardis Marco
Hawkins Rebecca
Snyder Linda
H Yamada Douglas
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NI201900009A publication Critical patent/NI201900009A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

Se describen métodos para tratar el cáncer de próstata al administrar niraparib a un sujeto que lo necesita.
NI201900009A 2016-07-29 2019-01-25 MÉTODOS PARA TRATAR EL CÁNCER DE PRÓSTATA Se describen métodos para tratar el c NI201900009A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662368466P 2016-07-29 2016-07-29
US201662369239P 2016-08-01 2016-08-01

Publications (1)

Publication Number Publication Date
NI201900009A true NI201900009A (es) 2019-05-10

Family

ID=59649991

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201900009A NI201900009A (es) 2016-07-29 2019-01-25 MÉTODOS PARA TRATAR EL CÁNCER DE PRÓSTATA Se describen métodos para tratar el c

Country Status (20)

Country Link
US (8) US20180028521A1 (es)
EP (1) EP3490560A1 (es)
JP (2) JP2019522032A (es)
KR (1) KR20190033599A (es)
CN (1) CN109640991A (es)
AU (2) AU2017302660B2 (es)
BR (1) BR112019001398A2 (es)
CA (1) CA3031705A1 (es)
CO (1) CO2019000753A2 (es)
DO (1) DOP2019000019A (es)
IL (1) IL264443A (es)
MA (1) MA45780A (es)
MX (1) MX2019001224A (es)
NI (1) NI201900009A (es)
PE (1) PE20190403A1 (es)
PH (1) PH12019500135A1 (es)
SG (1) SG11201900361RA (es)
SV (1) SV2019005822A (es)
UA (1) UA124972C2 (es)
WO (1) WO2018023017A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
JP2019522032A (ja) 2016-07-29 2019-08-08 ヤンセン ファーマシューティカ エヌ．ベー． 前立腺癌の治療方法
CN111801117A (zh) * 2017-12-27 2020-10-20 特沙诺有限公司 治疗癌症的方法
JP7456942B2 (ja) * 2018-05-16 2024-03-27 オンクターナル セラピューティクス，インコーポレイテッド 選択的アンドロゲン受容体分解剤（ｓａｒｄ）リガンドおよびその使用方法
US20210340122A1 (en) * 2018-09-05 2021-11-04 University Of Tennessee Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof
WO2023001746A1 (en) * 2021-07-19 2023-01-26 Janssen Pharmaceutica Nv Treatment of metastatic castration-resistant prostate cancer with niraparib

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2109608B1 (en) 2007-01-10 2011-03-23 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
CN106008460B (zh) 2008-01-08 2022-08-12 默沙东公司 2-{4-[(3s)-哌啶-3-基]苯基}-2h-吲唑-7-羧酰胺的药学可接受的盐
CA2723590C (en) 2008-05-07 2017-06-27 Cardioxyl Pharmaceuticals Inc. Novel nitroso compounds as nitroxyl donors and methods of use thereof
WO2012009475A1 (en) 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
WO2014089324A1 (en) 2012-12-07 2014-06-12 Calitor Sciences, Llc Substituted cyclic compounds and methods of use
EP3230472A4 (en) 2014-12-08 2018-06-13 Myriad Genetics, Inc. Methods and materials for predicting response to niraparib
JP2019522032A (ja) * 2016-07-29 2019-08-08 ヤンセン ファーマシューティカ エヌ．ベー． 前立腺癌の治療方法
JOP20190244A1 (ar) 2017-04-13 2019-10-13 Janssen Pharmaceutica Nv تركيبة علاجية لسرطان البروستاتا

Also Published As

Publication number Publication date
PE20190403A1 (es) 2019-03-13
JP2022122920A (ja) 2022-08-23
BR112019001398A2 (pt) 2019-05-07
SG11201900361RA (en) 2019-02-27
US20230149380A1 (en) 2023-05-18
US20190022079A1 (en) 2019-01-24
US20230078160A1 (en) 2023-03-16
CO2019000753A2 (es) 2019-02-08
US20220071980A1 (en) 2022-03-10
IL264443A (en) 2019-02-28
CN109640991A (zh) 2019-04-16
MA45780A (fr) 2019-06-05
DOP2019000019A (es) 2019-09-30
US20240000766A1 (en) 2024-01-04
EP3490560A1 (en) 2019-06-05
MX2019001224A (es) 2019-06-03
US11207311B2 (en) 2021-12-28
PH12019500135A1 (en) 2019-10-28
UA124972C2 (uk) 2021-12-22
KR20190033599A (ko) 2019-03-29
SV2019005822A (es) 2019-03-28
US20230098047A1 (en) 2023-03-30
AU2023202813A1 (en) 2023-05-25
AU2017302660B2 (en) 2023-04-20
JP2019522032A (ja) 2019-08-08
WO2018023017A1 (en) 2018-02-01
US20180028521A1 (en) 2018-02-01
US20220071979A1 (en) 2022-03-10
AU2017302660A1 (en) 2019-01-24
CA3031705A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
NI201900009A (es) MÉTODOS PARA TRATAR EL CÁNCER DE PRÓSTATA Se describen métodos para tratar el c
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
NI201900019A (es) Inhibidores de procesos metabólicos celulares
ECSP17070399A (es) Anticuerpos contra icos
SV2018005709A (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
CL2017002728A1 (es) Método para el tratamiento de cáncer
CR20150510A (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
CL2016000341A1 (es) Métodos para tratar la miositis por cuerpos de inclusión esporádica
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
AR097481A1 (es) Cocristales energéticos para el tratamiento de una formación subterránea
CL2015002571A1 (es) Composiciones y métodos para le diagnostico y tratamiento del cáncer hepático.
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
CL2015000715A1 (es) Anti-androgenos para el tratamiento de cáncer prostatico no metastasico y resistente de castracion
PH12017501879A1 (en) Methods for treating cancer
CL2016000379A1 (es) Composiciones y métodos terapéuticos para reducción acelerada de plagas
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
NI201500151A (es) Terapia de combinación que comprende un compuesto de dihidropirazino-pirazina y un antagonista de receptor de andrógenos para tratar cáncer de próstata.
BR112017013093A2 (pt) processos para a preparação de um composto de diariltio-hidantoína
NI201500055A (es) Tratamiento de cáncer de próstata con inhibidores de quinasa tor
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
MX2015013021A (es) 5-bromo-indirrubinas.